InMed Pharmaceuticals Inc (INM)

[Thedrugguru]

If the company can produce cannabinoids on a commercial scale, then there is no question that they have tremendous value. Given its current stock price, the market does not believe that they can. And a director dumping most of his shares is not a rational act if the company is close to being able to produce these cannabinoids. So the jury is still very much out as to whether the company can back up its claims. As for their drug candidates, they specifically targeted diseases with unmet needs as these are easier to get through trials and easier to get fast track designation. Given that they have been talking about these for over 2 years without being close to filing an IND calls into question the ability of their staff to get drugs into a pipeline on an efficient basis. Given the status of their drug pipeline, I assign it very little value. So it really gets down to biosynthesis for value. Adams talks a good game but has yet to produce.